Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease: a protocolized prospective observational study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease : a protocolized prospective observational study. / Kamstrup, Peter; Sivapalan, Pradeesh; Rønn, Christian; Rastoder, Ema; Modin, Daniel; Kristensen, Anna Kjaer; Bendstrup, Elisabeth; Sørensen, Rikke; Biering-Sørensen, Tor; Ulrik, Charlotte Suppli; Vestbo, Jørgen; Jensen, Jens Ulrik.
In: Respiratory research, Vol. 24, 172, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Fibrin degradation products and survival in patients with chronic obstructive pulmonary disease
T2 - a protocolized prospective observational study
AU - Kamstrup, Peter
AU - Sivapalan, Pradeesh
AU - Rønn, Christian
AU - Rastoder, Ema
AU - Modin, Daniel
AU - Kristensen, Anna Kjaer
AU - Bendstrup, Elisabeth
AU - Sørensen, Rikke
AU - Biering-Sørensen, Tor
AU - Ulrik, Charlotte Suppli
AU - Vestbo, Jørgen
AU - Jensen, Jens Ulrik
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Background: Patients with chronic obstructive pulmonary disease (COPD) have a high incidence of cardiovascular disease including thromboembolisms. Fibrin degradation products, like D-dimer, have been associated with death from all causes in healthy individuals and COPD patients. We aimed to determine the (i) association between D-dimer levels and all-cause mortality and time being alive and out of a hospital, (ii) possible modifying effect of anticoagulant treatment, and (iii) distribution of D-dimer in patients with moderate to severe COPD. Methods: Results of routinely measured stable phase D-dimer samples from COPD-outpatients at Copenhagen University Hospital – Herlev and Gentofte, COPD-outpatient clinic were collected using the Danish registries. These were used to examine whether COPD-patients with a D-dimer level in the upper quartile, had a higher risk of death from all causes within 365 days. Results: In the unadjusted Cox proportional hazards regression we found an association between high D-dimer and all-cause mortality: Hazard ratio (HR): 2.3 (95% Confidence Interval (CI) 1.1–4.7). In the fully adjusted regression, the HR was 1.8 (CI 0.8–3.9). We did not find any interaction between D-dimer and anticoagulant or antiplatelet therapy. For the secondary outcome, proportion of days alive and out of hospital in 365 days (pDAOH), the unadjusted multiple linear regression had an association between high D-dimer level and pDAOH: -2.7% points (pp) (CI -3.9 pp - -1.5 pp), which was attenuated to -1,7pp (-2.9pp – -0.4pp) in the fully adjusted regression. Conclusions: In patients with moderate to severe COPD, patients with a high level of D-dimer were more likely to die; however, the signal was not strong in the adjusted analyses and our results do not support unselected risk stratification with D-dimer in COPD-outpatients.
AB - Background: Patients with chronic obstructive pulmonary disease (COPD) have a high incidence of cardiovascular disease including thromboembolisms. Fibrin degradation products, like D-dimer, have been associated with death from all causes in healthy individuals and COPD patients. We aimed to determine the (i) association between D-dimer levels and all-cause mortality and time being alive and out of a hospital, (ii) possible modifying effect of anticoagulant treatment, and (iii) distribution of D-dimer in patients with moderate to severe COPD. Methods: Results of routinely measured stable phase D-dimer samples from COPD-outpatients at Copenhagen University Hospital – Herlev and Gentofte, COPD-outpatient clinic were collected using the Danish registries. These were used to examine whether COPD-patients with a D-dimer level in the upper quartile, had a higher risk of death from all causes within 365 days. Results: In the unadjusted Cox proportional hazards regression we found an association between high D-dimer and all-cause mortality: Hazard ratio (HR): 2.3 (95% Confidence Interval (CI) 1.1–4.7). In the fully adjusted regression, the HR was 1.8 (CI 0.8–3.9). We did not find any interaction between D-dimer and anticoagulant or antiplatelet therapy. For the secondary outcome, proportion of days alive and out of hospital in 365 days (pDAOH), the unadjusted multiple linear regression had an association between high D-dimer level and pDAOH: -2.7% points (pp) (CI -3.9 pp - -1.5 pp), which was attenuated to -1,7pp (-2.9pp – -0.4pp) in the fully adjusted regression. Conclusions: In patients with moderate to severe COPD, patients with a high level of D-dimer were more likely to die; however, the signal was not strong in the adjusted analyses and our results do not support unselected risk stratification with D-dimer in COPD-outpatients.
KW - All-cause mortality
KW - Biomarker
KW - Cohort
KW - COPD
KW - D-dimer
U2 - 10.1186/s12931-023-02472-9
DO - 10.1186/s12931-023-02472-9
M3 - Journal article
C2 - 37370121
AN - SCOPUS:85163716091
VL - 24
JO - Respiratory Research (Print)
JF - Respiratory Research (Print)
SN - 1465-9921
M1 - 172
ER -
ID: 365981068